On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to the Companyﾒs capacity under contract with Applied Pharmaceutical Innovation will focus on the synthesis of pharmaceutical grade mescaline.

Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression.